CAR-T (Chimeric Antigen Receptor T-cell) therapy is a groundbreaking advancement in cancer treatment. This innovative therapy involves modifying a patient’s T-cells, enabling them to target and destroy cancer cells. It has shown remarkable success in treating hematological malignancies, including lymphomas and leukemias.
Key Features of CAR-T Platform
- Autologous Therapy: Patient-derived T-cells are genetically engineered to target specific cancer antigens like CD19 or BCMA, ensuring precision treatment tailored to individual patients.
- Advanced Manufacturing Workflow: From T-cell collection through leukapheresis to genetic modification, expansion, and cryopreservation, each step adheres to stringent GMP standards. Technologies like the Sefia™ Select system streamline automation and reduce contamination risks.
- State-of-the-Art Equipment: Solutions like Sepax™ C-Pro for cell processing, Xuri™ systems for cell expansion, and VIA Freeze™ for cryopreservation ensure consistent quality and reproducibility.
Benefits of the Platform
- Personalized Therapy: Tailored treatments based on the patient’s unique cancer profile.
- Regulatory Compliance: Functionally closed systems like Cytiva’s Sefia meet FDA and EU Annex 11 requirements, ensuring data integrity and patient safety.
- Collaborative Ecosystem: Partnerships with global leaders like Cytiva and Pall enable access to cutting-edge technologies and expertise.
Applications in Turkey
TCT Sağlık is spearheading efforts to bring CAR-T therapies to Turkey, focusing on technology transfer, local production, and establishing fully integrated FlexFactory™ centers. These initiatives aim to make advanced cell therapies more accessible, contributing to Turkey’s biotechnology ecosystem.
For more details, explore our solutions or partner with us in transforming healthcare.